Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period ending March 29, 2016. The filing addresses corporate governance actions regarding preferred stock dividends and regulatory status updates with the NASDAQ Stock Market.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is a quarterly cash dividend declaration of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock.
Material Changes and Events
- Dividend Declaration: The Board declared a quarterly cash dividend of $0.15 per share on the 6% Convertible Exchangeable Preferred Stock. The dividend is payable on May 1, 2016, to holders of record as of April 18, 2016.
- NASDAQ Compliance: The Company received a favorable ruling from the NASDAQ Listing Qualifications Panel. The Panel granted an extension until June 14, 2016, to regain compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- Compliance Condition: To maintain listing, the Company must evidence a closing bid price of $1.00 per share or more for a minimum of ten prior consecutive trading days on or before June 14, 2016.
Guidance, Outlook, and Risks
Management stated that while the Board will analyze the advisability of declaring dividends in future quarters, there is no assurance that future quarterly dividends will be declared. The primary risk identified is the potential delisting from NASDAQ if the Company fails to meet the $1.00 minimum bid price requirement by the June 14, 2016 deadline.
Investor Verification Checklist
- Verify the Company's current stock price and trading volume to assess the likelihood of meeting the $1.00 minimum bid price requirement by June 14, 2016.
- Confirm the record date (April 18, 2016) and payment date (May 1, 2016) for the $0.15 preferred stock dividend.
- Review the attached press release (Exhibit 99.1) for the full text of the NASDAQ Panel ruling.
- Monitor future filings for updates on the Company's plan to regain compliance with NASDAQ listing standards.